Antimitotic Activity of 5-Hydroxy-7-methoxy-2-phenyl-4-quinolones
- 26 August 2004
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 47 (20) , 4964-4970
Abstract
We report the synthesis of 5-hydroxy-7-methoxy-2-phenyl-4-quinolones and their biological activity as antitumor agents. These molecules were initially evaluated for their ability to induce cell cycle arrest in the G2/M phase. Compounds that showed significant G2/M cell cycle arrest were tested for antiproliferative activity using both the MTT assay and the NCI in vitro 60 cell line human tumor screen. The 5-hydroxy-7-methoxy-2-phenyl-4-quinolone (3a) and 2-(3-fluorophenyl)-5-hydroxy-7-methoxy-4-quinolone (3f) were the most active in the cell cycle arrest test whereas 3f was found to be the most active in the MTT assay. In terms of structural requirements, we found that the presence of a 5-hydroxyl group, a 7-methoxy group, and an unsubstituted N1 were essential for the antimitotic activity. In accordance with the literature, a fluoro group at the 3‘- or 2‘-position and a methoxy or a chloro group at the 3‘-position were found to be highly advantageous for both the cell cycle arrest and the antiproliferative activities.Keywords
This publication has 9 references indexed in Scilit:
- Recent advances in the discovery of flavonoids and analogs with high‐affinity binding to P‐glycoprotein responsible for cancer cell multidrug resistanceMedicinal Research Reviews, 2002
- Inactivation of wild-type p53 by a dominant negative mutant renders MCF-7 cells resistant to tubulin-binding agent cytotoxicityBritish Journal of Cancer, 2001
- A Comparative Molecular Field Analysis of Inhibitors of Tubulin PolymerizationQuantitative Structure-Activity Relationships, 2000
- Tubulin as a target for anticancer drugs: Agents which interact with the mitotic spindleMedicinal Research Reviews, 1998
- Structure−Activity Requirements for Flavone Cytotoxicity and Binding to TubulinJournal of Medicinal Chemistry, 1998
- Crystal structure of the Src family tyrosine kinase HckNature, 1997
- Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase.Proceedings of the National Academy of Sciences, 1996
- The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeuticsPharmacology & Therapeutics, 1991
- Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4Cellular and Molecular Life Sciences, 1989